G2gbio KRX:456160KOSDAQ
지투지바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days11
DART filings, 7 days1
Articles tracked89since Sep 11
In Q2 2026, G2gbio reported revenue of ₩1.6bn, up 944.7% year on year, and an operating loss of ₩2.7bn. G2gbio (지투지바이오) appeared in 11 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 19 with 24 articles. The most common catalyst was contracts & orders (9). It was most often mentioned alongside Inventera, 글로벌테크놀로지 and Lemon Healthcare.
Filing signals 4 quarters of losses Screener
G2gbio quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩1.6bn | +944.7% | −₩2.7bn margin −168.6% | −₩5.7bn |
| Q1 2026 | ₩351m | +4364.3% | −₩3.3bn | −₩5.5bn |
| Q4 2025 derived | ₩203m | – | −₩3.0bn | −₩2.8bn |
| Q3 2025 | ₩58m | -71.0% | −₩3.6bn | −₩3.5bn |
| Q2 2025 | ₩153m | +90.0% | −₩2.7bn | −₩2.9bn |
| Q1 2025 | ₩8m | -98.4% | −₩2.9bn | −₩2.9bn |
| Q4 2024 derived check units | −₩2m | – | −₩3.3bn | −₩3.2bn |
| Q3 2024 | ₩202m | +941.4% | −₩2.8bn | −₩2.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
G2gbio top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5
- 6
Latest G2gbio news Korean headlines
-
中 제약사 손잡은 지투지바이오 ‘上’…인벤테라는 美 임상 청신호 [바이오 맥짚기]
1 more on this story · 1 outlets
- 中 제약사 손잡은 지투지바이오 ‘上’…인벤테라는 美 임상 청신호 [바이오 맥짚기]이데일리 · Oct 21 08:01
-
Featured지투지바이오, 中 제약사와 플랫폼 평가 계약에 급등
1 more on this story · 1 outlets
- 지투지바이오, 中 제약사와 플랫폼 평가 계약에 급등한민족센터 · Oct 20 15:46
-
Featured지투지바이오, 中 UBT와 협력 소식에 '급등'
1 more on this story · 1 outlets
- [ET특징주]지투지바이오, 中 UBT와 협력 소식에 상승세전자신문 · Oct 20 14:06
-
Featured지투지바이오, 中 바이오텍 '장기지속 주사제' 계약 13% 급등
1 more on this story · 1 outlets
- 지투지바이오, 中 기업 '장기지속 주사제' 계약 소식에 10%대 급등매일신문 · Oct 20 10:21